ABC News: How AI is Transforming Drug Discovery
Christian Olsen, VP of Biologics at Dotmatics, explains in an ABC News interview how AI is transforming pharmaceutical R&D by accelerating drug target identification and high-throughput screening, thereby significantly reducing the time and cost of drug discovery and enabling breakthroughs in diseases like cancer, diabetes, cardiovascular conditions, and neurology.
Artificial intelligence is revolutionizing drug discovery, potentially slashing the decade-long timeline and billion-dollar costs associated with bringing new medicines to market. In this interview, Christian Olsen, VP of Biologics at Dotmatics, discusses how AI is reshaping pharmaceutical R&D by accelerating drug target identification and high-throughput screening. By leveraging vast datasets and automation, AI enables scientists to uncover new treatment strategies and revisit overlooked therapeutic opportunities.
AI is driving breakthroughs in areas such as cancer, diabetes, cardiovascular disease, and neurology. Dotmatics is empowering pharmaceutical and biotech companies to develop life-saving treatments faster than ever before.
Related
NBC News: How AI is Transforming Drug Discovery
In an NBC News segment, Alister Campbell, VP of Dotmatics, explains how the company leverages AI to analyze large datasets, predict effective drug compounds, and streamline fragmented data systems and manual workflows, thereby accelerating and improving the efficiency of drug discovery.
Reasonable Expectations, Clean Data, Collaboration: The Three Keys to AI in Drug Discovery
The article explains that while AI and machine learning have long been used in drug discovery, recent hype and massive investments have led to unrealistic expectations, emphasizing that success depends on setting reasonable goals, ensuring clean and abundant data, and fostering collaboration, as most AI-driven drug candidates remain in early development stages and face complex biological and practical challenges.
KRON TV: AI in Medicine From Research Assistant to Predictive Partner
In a KRON-TV interview, Dotmatics VP Phil Mounteney discusses how AI is evolving from a research assistant automating data tasks to a predictive partner that accelerates drug discovery by identifying new targets, designing molecules, and enabling personalized therapies, ultimately reducing costs and time to market while expanding patient access to safer, tailored medicines.
CBS News: How AI Is Accelerating Safer, More Personalized Drug Discovery
In a CBS News interview, Dotmatics VP Phil Mounteney explains how their internally developed AI models accelerate drug discovery by analyzing early-phase research data to shorten development cycles, reduce costs, and deliver safer, personalized therapies while maintaining data privacy.
Techstrong TV: AI Leadership Insights for Scientific Research and Drug Discovery
In this Techstrong TV interview, Dotmatics CEO Thomas Swalla discusses how the company leverages AI to accelerate scientific research and drug discovery by streamlining workflows, enabling breakthroughs, and reducing costs in R&D.
The Role of Artificial Intelligence in the Modern R&D Lab
Thomas Swalla, CEO of Dotmatics, explains how artificial intelligence integrated into Dotmatics' software platform helps modern R&D labs by automating data analysis, breaking down data silos, reducing research costs, and accelerating the discovery of medical therapies.